Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children

Pediatric Critical Care Medicine

Volumn 7, Issue 5, 2006, Pages 434-439

  Wolf, Gerhard K ^a   McClain, Craig D ^a,b   Zurakowski, David ^b   Dodson, Brenda ^a,b   McManus, Michael L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Critical care; Hypoalbuminemia; Intoxication; Pediatric; Phenytoin; Seizures; Sheiner Tozer equation; Well stirred model

Indexed keywords

CEFAZOLIN; CLONAZEPAM; DIAZEPAM; ETIRACETAM; LORAZEPAM; MIDAZOLAM; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; SERUM ALBUMIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; CONCENTRATION RESPONSE; CRITICAL ILLNESS; DRUG BINDING; DRUG INTOXICATION; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NEWBORN; NONLINEAR SYSTEM; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEIZURE;

EID: 33748636261     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000235252.43921.DE     Document Type: Article

References (34)

1. Martin E, Tozer TN, Sheiner LB, et al: The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm 1977; 5:579-96
2. Richens A, Dunlop A: Serum-phenytoin levels in management of epilepsy. Lancet 1975; 2:247-248
3. Borofsky LG, Louis S, Kutt H, et al: Diphenylhydantoin: Efficacy, toxicity, and dose-serum level relationships in children. J Pediatr 1972; 81:995-1002
4. Lund L: Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol 1974; 31:289-294
5. Boucher BA, Rodman JH, Jaresko GS, et al: Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988; 44:675-683
6. Bailey DN, Briggs JR: The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004; 26:40-43
7. Lindow J, Wijdicks EF: Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994; 105:602-604
8. Driscoll DF, McMahon M, Blackburn GL, et al: Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations. Crit Care Med 1988; 16:1248-1249
9. Appleton RE, Gill A: Adverse events associated with intravenous phenytoin in children: A prospective study. Seizure 2003; 12:369-372
10. Craig S: Phenytoin overdose complicated by prolonged intoxication and residual neurological deficits. Emerg Med Australas 2004; 16:361-365
11. Craig S: Phenytoin poisoning. Neurocrit Care 2005; 3:161-170
12. Earnest MP, Marx JA, Drury LR: Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 1983; 249:762-765
13. Randazzo DN, Ciccone A, Schweitzer P, et al: Complete atrioventricular block with ventricular asystole following infusion of intravenous phenytoin. J Electrocardiol 1995; 28:157-159
14. Sheiner LB, Tozer TN: Clinical pharmacokinetics: The use of plasma concentrations of drugs. In: Clinical Pharmacology: Basic Principles in Therapeutics. Melmon KL, Morelli HF (Eds). New York, Macmillan, 1978, pp 71-109
15. Mauro LS, Mauro VF, Bachmann KA, et al: Accuracy of two equations in determining normalized phenytoin concentrations. DICP 1989; 23:64-68
16. Johnson GJ, Kilpatrick CJ, Bury RW, et al: Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate - The predictive value of plasma albumin concentration. Br J Clin Pharmacol 1989; 27:843-849
17. Theodore WH, Yu L, Price B, et al: The clinical value of free phenytoin levels. Ann Neurol 1985; 18:90-93
18. Pospisil J, Perlik F: Binding parameters of phenytoin during monotherapy and polytherapy. Int J Clin Pharmacol Ther Toxicol 1992; 30:24-28
19. Mamiya K, Yukawa E, Matsumoto T, et al: Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin Neuropharmacol 2002; 25:230-233
20. Domke I, Cremer P, Huchtemann M: Therapeutic drug monitoring on COBAS INTEGRA 400 - Evaluation results. Clin Lab 2000; 46:509-515
21. Stamp RJ, Mould GP, Muller C, et al: Performance of fluorescence polarisation immunoassay reagents for carbamazepine, phenytoin, phenobarbitone, primidone, and valproic acid on a Cobas Fara II analyser. Ther Drug Monit 1991; 13:518-522
22. Roberts WL, Annesley TM, De BK, et al: Performance characteristics of four free phenytoin immunoassays. Ther Drug Monit 2001; 23:148-154
23. Winter MG, Tozer TN. Phenytoin. In: Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Third Edition. Evans WE, Schentag JJ, Jusko WJ (Eds). Vancouver, BC, Lippincott Williams & Wilkins, 1992, pp. 1-44
24. Mlynarek ME, Peterson EL, Zarowitz BJ: Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother 1996; 30:219-223
25. Armitage PBG, Matthews JNS. Statistical Methods in Medical Research. Fourth Edition. Oxford, UK. Blackwell Science, 2002
26. Medina LS, Zurakowski D: Measurement variability and confidence intervals in medicine: Why should radiologists care? Radiology 2003; 226:297-301
27. Draper NR, Smith H. Applied Regression Analysis. Third Edition. New York, John Wiley, 1998
28. Durward A, Mayer A, Skellett S, et al: Hypoalbuminaemia in critically ill children: Incidence, prognosis, and influence on the anion gap. Arch Dis Child 2003; 88:419-422
29. Anderson GD, Pak C, Doane KW, et al: Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997; 31:279-284
30. Pang KS, Rowland M: Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 1977; 5:681-699
31. Pang KS, Rowland M: Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation J Pharmacokinet Biopharm 1977; 5:655-680
32. Pang KS, Rowland M: Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model: Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance J Pharmacokinet Biopharm 1977; 5:625-653
33. Peterson GM, Khoo BH, von Witt RJ: Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991; 13:415-419
34. Jannuzzi G, Cian P, Fattore C, et al: A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000; 41:222-230